Stockholm Calls: Docs Eye New Tactics for Type 2 Diabetes at EASD Stockholm Calls: Docs Eye New Tactics for Type 2 Diabetes at EASD
New data on tirzepatide for weight loss and potential type 2 diabetes remission as well as an update on use of dapagliflozin for heart failure will be presented at the first in-person EASD meeting for 3 years.Medscape Medical News
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
More News: Cardiology | Dapagliflozin | Diabetes | Diabetes Type 2 | Endocrinology | Forxiga | Heart | Heart Failure | Weight Loss